Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Approvals Cardiology Clinical Trials

FDA Approves Shockwave Coronary Intravascular Lithotripsy System

  • News

Executive Summary

Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.

You may also be interested in...



Shockwave Prepares For FDA Approval Of Coronary Intravascular Lithotripsy System

The company expects the FDA to approve its intravascular lithotripsy system with the C2 coronary catheter in early 2021 based on results from the Disrupt CAD III study.

Start-Up Scanwell Adds Another Collaboration, Targets Home COVID-19 Testing With BD

Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.  

NuVasive Adds Artificial Cervical Disc By Acquiring Simplify For $150M

Simplify’s total disc replacement complements NuVasive’s C360 line of cervical repair surgery devices, addressing a market that could eventually be worth $2.6bn.

Table

View full table

Topics

Tags:
Approvals Cardiology Clinical Trials
UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By